ArticleCureus2025
Post-operative Stereotactic Radiosurgery to Brain Metastases Cavity: A Large, Observational Single-Centre Series From the United Kingdom.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Stereotactic radiosurgery (SRS) is widely regarded as the standard of care after the resection of brain metastases in order to reduce local cavity recurrence risk. The objective of this study was to explore the reproducibility of published outcomes for patients receiving post-operative stereotactic radiosurgery (cavity SRS) in a National Health Service (NHS) setting for a non-selective series of patients. For our service, the median interval between surgery to cavity SRS (cSRS) is eight weeks, whereas similar timelines have been found to have a deleterious impact on survival in the published literature. Materials and methods This retrospective cohort study analysed outcomes for 100 consecutive cSRS patients treated between 2015 and 2019 at a Northern English cancer centre. A case note review was conducted, with collection of primary tumour, disease extent, SRS treatment details and outcome data. Results Median survival for all primaries was 16 months, with renal, melanoma and breast having optimum survival at 28, 26 and 17 months, respectively. Local relapse was seen in 6/100 patients, with a further 6/100 patients having leptomeningeal disease. Radionecrosis was rare (3/100). Dose prescription, size of PTV and number of metastatic sites did not produce a statistically significant impact on survival times. The detrimental impact of delay from surgery to SRS beyond 56 days reported by others was not evident in our series (p-value 0.786). Conclusion SRS to the surgical cavity after the resection of brain metastases in eligible patients produces favourable outcomes and demonstrates outcomes comparable to the world literature. Our study does not demonstrate a significant drop in survival with delay beyond eight weeks to cSRS, which may reflect a different cause of delay in our NHS setting than in other healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.